Second-Generation Antipsychotics During the Lactation Period A Comparative Systematic Review on Infant Safety

Basit Öğe Kaydı
dc.contributor.authorUguz, Faruk
dc.date.accessioned2024-02-23T14:21:11Z
dc.date.available2024-02-23T14:21:11Z
dc.date.issued2016
dc.departmentNEÜen_US
dc.description.abstractObjective: This review examined the safety of second-generation antipsychotics (SGAs) in exposed breastfed infants. Methods: PubMed was searched for English language reports between January 1, 1990, to June 30, 2015, by using combinations of the key words breastfeeding, lactation, postpartum period, puerperium, antipsychotics, second-generation antipsychotics, olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, amisulpride, clozapine, asenapine, lurasidone, and iloperidone. Case reports, case series, and prospective or cross-sectional studies including relevant data such as relative infant dose (RID), milk-to-plasma ratio (M/P ratio), infant drug plasma levels, and adverse events were identified. Results: A total of 37 relevant reports were examined. These reports included a total of 206 infants exposed to olanzapine (n = 170), quetiapine (n = 14), risperidone/paliperidone (n = 8), clozapine (n = 6), aripiprazole (n = 4), ziprasidone (n = 2), and amisulpride (n = 2). Approximately half of the available data on the M/P ratio, RID, and infant drug plasma levels included olanzapine. Relatively adequate reports suggest that olanzapine has low RID values. Limited reports suggest low RID values for quetiapine and ziprasidone, moderate RID values for risperidone/paliperidone and aripiprazole, and high RID values for amisulpride. Antipsychotic levels were undetectable in the plasma of most of the exposed infants. Other than clozapine, adverse events were rarely reported in infants exposed to SGAs. Conclusions: The current data suggest that SGAs seem to be relatively safe in the exposed breastfed infants for short-term usage. However, additional studies, in particular for antipsychotics other than olanzapine, examining short-term and especially long-term effects of SGAs on the breastfed infants are required.en_US
dc.identifier.doi10.1097/JCP.0000000000000491
dc.identifier.endpage252en_US
dc.identifier.issn0271-0749
dc.identifier.issn1533-712X
dc.identifier.issue3en_US
dc.identifier.pmid27028982en_US
dc.identifier.scopus2-s2.0-84961960553en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage244en_US
dc.identifier.urihttps://doi.org/10.1097/JCP.0000000000000491
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13475
dc.identifier.volume36en_US
dc.identifier.wosWOS:000375089900009en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal Of Clinical Psychopharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreastfeedingen_US
dc.subjectAntipsychoticsen_US
dc.subjectPostpartum Perioden_US
dc.titleSecond-Generation Antipsychotics During the Lactation Period A Comparative Systematic Review on Infant Safetyen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu